All Posts Tagged With: "JNJ"
(PG) Procter & Gamble Results Come Up Short on Charges
Procter & Gamble Co.(PG) reported modest results for the second quarter 2012, with net earnings from continuing operations sliding 49.0% year over year to 57 cents a share, which missed the Zacks Consensus Estimate by 47.22%. Profits were limited due to non-core charges...
30Jan2012 | vitalstocks | 0 comments | Continued(EU) Stock Market News for January 25, 2012 – Market News
In yet another calm trading session, markets were pulled slightly lower after Eurozone ministers rejected a bond swap offer from Greece’s private creditors. While the Dow dropped lower and the S&P 500 reversed its five-day winning streak, Nasdaq added meager points after...
25Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Mixed Earnings, Greece May Slip Markets
With nothing major on the domestic economic calendar, headlines about Greece’s as-yet unsuccessful negotiations with its bondholders to restructure its private debt may get some traction. But today’s market action will be mostly about the slew of mixed earnings reports from...
24Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Jan 24: Day of Earnings! – Economic Highlights
With nothing major on the domestic economic calendar, headlines about Greece’s as-yet unsuccessful negotiations with its bondholders to restructure its private debt may get some traction. But today’s market action will be mostly about the slew of mixed earnings reports from...
24Jan2012 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals
The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&A) deals have taken place in the pharma sector over the last couple of years. With most...
9Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(JNJ) Spotlight on Hepatitis-C Market
Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech companies...
7Dec2011 | vitalstocks | 0 comments | Continued(GILD) Gilead’s Eviplera Drug is Cleared by European Medicines Agency
Gilead Sciences, Inc (GILD), the world’s largest HIV drug maker, received marketing authorization from the European Medicines Agency (EMA) for the single tablet regimen (STR), Eviplera, for the treatment of HIV in previously untreated adults. The STR combines Gilead’s marketed...
30Nov2011 | vitalstocks | 0 comments | Continued(CRDC) Cardica Reaches Second Milestone for Their Microcutter
Surgical devices maker Cardica (CRDC) has achieved the second milestone for its Microcutter product line under its distribution pact with Century Medical, a leading supplier of medical equipment in Japan. The Microcutter line of novel endoscopic stapling devices is geared for...
28Nov2011 | vitalstocks | 0 comments | Continued(MMM) 3M Company Analyst Reiterates Shares at Neutral
We recently maintained a Neutral recommendation on3M Company (MMM). Based in St. Paul, Minnesota, 3M is a diversified technology company with manufacturing operations spread over 60 countries worldwide. It has more than 35 business units organized into six segments: Consumer...
28Nov2011 | vitalstocks | 0 comments | Continued(JNJ) Bayer Cut to Underperform
We recently downgraded Bayer (BAYRY) to Underperform from Neutral purely on valuation grounds. We believe that the stock is overvalued at current levels. Even though the US Food and Drug Administration (FDA) cleared Bayer/ Johnson & Johnson’s (JNJ) potential blockbuster...
23Nov2011 | vitalstocks | 0 comments | Continued(MMM) 3M Company 2011 Third Quarter Earnings Scorecard
3M Company (MMM) reported modest results for the third quarter of 2011. The company achieved year-over-year top-line growth of 9.6%, as five out of six segments saw revenue growth. The bottom-line slipped 1% however, missing our estimate by 9 cents. Third Quarter Highlights Total...
22Nov2011 | vitalstocks | 0 comments | Continued(MDT) Medical Technology Industry Stock Outlook – November 2011 – Industry Outlook
The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures,...
18Nov2011 | vitalstocks | 0 comments | Continued(SYK) Stryker Third Quarter 2011 Earnings Scorecard
Orthopedic devices giant Stryker Corporation’s (SYK) third-quarter 2011 adjusted (excluding acquisition charges) earnings per share of 91 cents topped the Zacks Consensus Estimate of 89 cents and the year-ago earnings of 80 cents. Third Quarter Flashback Profit (as reported)...
7Nov2011 | vitalstocks | 0 comments | Continued(JNJ) Johnson & Johnson 2011 Third Quarter Earnings Scorecard
Following the release of third quarter 2011 results, majority of the analysts covering Johnson & Johnson (JNJ) revised their earnings estimates. While 2011 estimates have been revised in both directions, 2012 estimates have gone predominantly downwards. Third Quarter Recap Johnson...
6Nov2011 | vitalstocks | 0 comments | Continued(GB) Greatbatch Analyst Raises Shares to Outperform
We upgrade our recommendation on Greatbatch (GB) to Outperform following its impressive third-quarter 2011 results. Adjusted earnings of 41 cents for the quarter outstripped the Zacks Consensus Estimate of 34 cents. Profit surged 17% year over year. Sales rose 3% year over year...
6Nov2011 | vitalstocks | 0 comments | Continued(DNDN) Dendreon Loss Narrows
Dendreon Corporation (DNDN) reported third-quarter 2011 loss (including stock-based compensation expense but excluding other special items) of 67 cents per share, which was narrower than the Zacks Consensus Estimate of 70 cents due to a slightly better-than-expected performance...
6Nov2011 | vitalstocks | 0 comments | Continued(PRGO) Perrigo Beats Earnings Forecast – Sales Miss
Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of 87 cents per share. Light sales performance was offset by a lower tax rate to drive earnings growth. First...
2Nov2011 | vitalstocks | 0 comments | Continued(GB) Greatbatch Third Quarter 2011 Earnings Helped By Medical Business
Greatbatch’s (GB) third-quarter fiscal 2011 adjusted (excluding one-time items) earnings per share of 41 cents outpaced both the Zacks Consensus Estimate and the year-ago adjusted earnings of 34 cents. Profit (as reported) soared 17% year over year to roughly $7 million (or...
2Nov2011 | vitalstocks | 0 comments | Continued(VRTX) Vertex Pharmaceuticals Riding High on Incivek Sales
Vertex Pharmaceuticals Inc. (VRTX) posted robust third quarter 2011 earnings (including stock-based compensation expense) of 56 cents per share, substantially above the Zacks Consensus Estimate of 19 cents and the year-ago loss of 99 cents. Increased revenues from the sale of...
2Nov2011 | vitalstocks | 0 comments | Continued(AAPL) A Busy Week Ahead – Earnings Preview
Earnings Preview 10/14/11 While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&P 500. Thus, by the end of the week we will have a very...
17Oct2011 | vitalstocks | 0 comments | Continued(MCD) A Smart Play in Down Markets – Multinational Stocks
by Jason Jenkins, Investment U Research Thursday, October 6, 2011 What do you do in a bear market? Most people would tell you to run and get out. Thousands of investors are flocking to the perceived safety of Treasury bonds. But as Alexander Green writes, the Treasury bond market...
10Oct2011 | InvestmentU | 0 comments | Continued(ENZN) Enzon Pharmaceuticals Plans a 50% Workforce Cut
Enzon Pharmaceuticals (ENZN) recently announced that it will reduce its workforce by almost half to better align its resources with much tempered pipeline activities. The research and development pipeline at Enzon was reduced drastically in the last few months. During the second...
27Sep2011 | vitalstocks | 0 comments | Continued(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
23Sep2011 | vitalstocks | 0 comments | Continued(WMGI) Wright Medical Group Gets a New CEO
International orthopedic devices company Wright Medical Group (WMGI) recently reported that its Board of Directors chose Mr. Robert J. Palmisano as President and CEO, starting from September 17, 2011. Mr. David D. Stevens, who was interim President and CEO, will remain Chairman...
21Sep2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca Coverage Initiated at Neutral
We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca’s business can be broken down into separate lines...
21Sep2011 | vitalstocks | 0 comments | Continued(BAC) Market Outlook Murky – Valuations Compelling
The Earnings Picture Second quarter earnings season is over; the attention now shifts to the third quarter. With the exception of a handful of financials, most notably Bank of America (BAC), which had a $12 billion negative swing in net income from last year, this has been another...
20Sep2011 | vitalstocks | 0 comments | Continued(WMGI) Wright Medical Group to Restructure
International orthopedic devices company Wright Medical Group (WMGI) recently reported that it is exercising a cost restructuring initiative to improve profitability, promote growth and strengthen cash flow, leading to enhanced shareholder value. The company believes that the...
20Sep2011 | vitalstocks | 0 comments | Continued(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell
We recently downgraded our rating on Enzon Pharmaceuticals Inc. (ENZN) from Neutral to Underperform with a target price of $9.50. In mid-May 2011, Enzon announced plans to halt the development of its lead pipeline compound PEG-SN38 (EZN-2208), a PEGylated version of the active...
15Sep2011 | vitalstocks | 0 comments | Continued(DNDN) Dendreon Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Dendreon Corporation (DNDN) with a target price of $13 per share after appraisal of the second quarter 2011 results. Dendreon Corporation reported weaker-than-expected second quarter 2011 sales of $49.6 million of its potential blockbuster...
14Sep2011 | vitalstocks | 0 comments | Continued